🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Insulin resistant vs. #insulin resistant phenotypes #T2D #diabetes Semaglutide vs. Dapagliflozin Nature Metabolism nature.com/articles/s4225… Open label 6 month observation trial

Precision medicine in type 2 diabetes - our new Exeter Med School paper in Diabetologia developing a treatment selection model for GLP1-RA & SGLT2i treatments using Bayesian Causal Forests link.springer.com/article/10.100… Web calc using routine clinical features: pm-cardoso.shinyapps.io/SGLT2_GLP1_cal…

All models are wrong and yours are useless! In case you missed my talk yesterday on how to make clinical prediction tools useful for patients, you can read all about it here. Enjoy! doi.org/10.1038/s41698…

Sex differences in T2D drug response matter! A greater glycaemic efficacy of GLP1-RA in females seen in our modelling study confirmed in GRADE RCT data (Liraglutide Male:female odds ratio glycaemic failure 1.63 [95%CI 1.20-2.22]) ADA Professional Publications Diabetes UK diabetesjournals.org/care/article/d…

Precision medicine in #type2diabetes: Cardoso et al develop a new approach for phenotype-based targeting of SGLT2-inhibitors and GLP1-receptor agonists tinyurl.com/bp89t8aa🔓 Exeter Med School John Dennis Angus Jones

Congratulations ExeterDiabetes University of Exeter Faculty of Health & Life Sci 🥂 What an amazing scoop of awards at #DUKPC24 Especially proud of our very own Christiana Lekka funded by the SMF Grand Challenge @stevemorganfdn @JDRFUK Diabetes UK Research

New Comment from Katherine Young, John Dennis and Nicholas Thomas on the challenges of detecting childhood #diabetes in primary care. Exeter Med School Read it here: thelancet.com/journals/landi…

UK primary care data suggests SGLT2i are effective in adults aged ≥70 years, but increase risk for genital infections and diabetic ketoacidosis Diabetologia link.springer.com/article/10.100…

We found 14 re-analyses that delivered evidence that we considered both credible and clinically important. Many of these were IPDMA, combining databases. Among these 14, there were 10 simple ‘risk modeling’ studies. Interestingly, >half of these showed variation in both absolute

Precision medicine in type 2 #diabetes: the causal analysis by Güdemann et al demonstrates that SGLT2 inhibitors are effective in older adults with #T2D but increase genital infections and #DKA risk tinyurl.com/p6pvhvb8 🔓 Exeter Med School Laura Güdemann Angus Jones

We are hiring: a graduate research assistant and 2x postdocs for a diabetes project using advanced in vitro methods. Collab w/ Thomas Piers and a cracking team of Co-Is GDRA: lnkd.in/eSwkfNHT PDRAx2: lnkd.in/efvA643b Exeter Med School #IPSC #Organoids #OOC

‼️Kidney protection in diabetes: Who is going to benefit more? #EASD2024

💥Those of us working in science comms are perhaps too fond of the word "gamechanging" but this research by John Dennis @athattersley ExeterDiabetes, published today in The Lancet and announced at #DUKPC25, truly deserves that description 💥 #Type2Diabetes #BetterCare

A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study hubs.li/Q038lTXc0

📢 Can AI help pick the best glucose-lowering drug❓ "Computer says yes" 🔹 Machine-learning model predicts optimal therapy (GLP-1RA, SGLT2i, SU, DPP4i, or TZD) 🔸 Model-concordant Rx = 5.3 mmol/mol ⤵️ HbA1c at 12m vs. non-optimal choices 🔹 Better long-term outcomes: 38% ⤵️

Prof Andrew Hattersley’s powerful opener 💬 “I’ve been in diabetes research for 35 years and this is the most impactful and important bit of work I’ve been involved in.” Read more: diabetes.org.uk/about-us/news-…

Next up on the stage of #DUKPC: Professor Ines Barroso Inês Barroso shares insights from her #research journey, showing how her expertise in genetics is helping to answer key questions for people living with #diabetes— all in her inspiring Dorothy Hodgkin Lecture. 🧬